BioRestorative Therapies (BRTX) AI Stock Analysis

• Market Cap: $11.95M
• Dividend Yield: N/A
• Average Volume (3M): 228.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: 247.62%
• EPS Growth: -7.66%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 8,656,242
• 10 Day Avg. Volume: 37,485
• 30 Day Avg. Volume: 228,790
• PEG Ratio: 0.02
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 27.69
• P/FCF Ratio: -1.33
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: ―

BioRestorative Therapies faces significant financial challenges with ongoing net losses and negative cash flow, affecting its stock performance. However, recent improvements in financial metrics, substantial revenue growth, and promising clinical developments provide some optimism. Technical indicators suggest a neutral market position. Although valuation remains a concern due to the lack of profitability, the company's strategic focus on clinical trials and research offers potential for future growth.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful advancement of clinical programs, enhancing long-term business prospects.

FDA Fast Track Designation

The FDA Fast Track designation for BRTX-100 accelerates its development and review process, potentially leading to faster market entry and revenue generation.

Strong Financial Position

A strong cash position with no debt provides financial stability, enabling continued investment in R&D and strategic initiatives without immediate financial pressure.

Negative Factors

Ongoing Financial Losses

Persistent financial losses highlight operational challenges and the need for sustainable revenue streams to achieve profitability, impacting long-term viability.

Negative Cash Flow

Negative cash flow indicates reliance on external financing, which may not be sustainable long-term, potentially affecting the company's operational capabilities.

Uncertain Licensing Outcomes

Uncertain outcomes in licensing agreements could delay revenue generation from partnerships, affecting strategic growth and market expansion plans.

BioRestorative Therapies Business Overview & Revenue Model

Company Description

BioRestorative Therapies (BRTX) is a biotechnology company focused on the development of innovative therapeutic solutions using cell and tissue therapies. The company operates primarily in the field of regenerative medicine, with a particular emphasis on stem cell-based therapies for the treatment of chronic lumbar disc disease and metabolic disorders. Its core products include BRTX-100, a stem cell-based therapeutic targeting disc/spine disease, and ThermoStem, a program focused on metabolic disorders including obesity and diabetes.

How the Company Makes Money

BioRestorative Therapies generates revenue through the development and commercialization of its proprietary cell and tissue-based therapeutic products. The company aims to earn revenue by advancing its clinical programs through various stages of regulatory approval, ultimately leading to product commercialization and sales. Key revenue streams include potential licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies interested in its therapies. Additionally, BRTX may secure funding from grants and research subsidies as it progresses its clinical trials and expands its research initiatives. However, being a biotechnology company in the developmental stage, BioRestorative Therapies may also rely on equity financing and other forms of investment to support its operations until its therapies are fully developed and marketed.

BioRestorative Therapies Financial Statement Overview

Summary

BioRestorative Therapies is in a challenging financial position with consistent net losses and negative cash flows, despite some revenue growth. While the balance sheet shows reduced leverage and improved equity, the company's ability to generate cash and achieve profitability remains a significant concern. Continued focus on cost management and operational efficiency will be crucial for financial stability.

Income Statement

BioRestorative Therapies shows a significant increase in revenue year-over-year, but it remains small in absolute terms. Despite this, the company struggles with negative profitability metrics, including persistent net losses and negative EBIT and EBITDA margins, indicating ongoing operational challenges and high costs relative to revenue.

Balance Sheet

The company has improved its equity position with positive stockholders' equity, and it has no current total debt, reducing financial risk. However, the frequent large net losses impact the overall asset quality, and the equity ratio has been declining, signaling a need for better asset management.

Cash Flow

Operating cash flow has been consistently negative, reflecting ongoing cash outflows from operations. While free cash flow has seen slight improvement, it remains negative, indicating cash burn. The reliance on financing activities to support cash needs is evident, which may not be sustainable long-term without improved operational cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	605.20K	401.00K	145.80K	119.80K	46.00K	77.00K
Gross Profit	571.98K	372.93K	-19.93K	119.80K	46.00K	77.00K
EBITDA	-12.94M	-11.37M	-10.25M	-18.85M	-26.22M	-9.48M
Net Income	-10.72M	-8.98M	-10.42M	-13.22M	-44.30M	-11.27M
Balance Sheet
Total Assets	8.52M	12.28M	12.61M	16.43M	22.45M	4.35M
Cash, Cash Equivalents and Short-Term Investments	7.38M	10.73M	11.07M	14.75M	21.03M	3.06M
Total Debt	0.00	0.00	162.32K	301.64K	670.70K	4.79M
Total Liabilities	3.67M	3.75M	2.61M	6.14M	856.50K	5.68M
Stockholders Equity	4.85M	8.53M	10.00M	10.29M	21.60M	-1.33M
Cash Flow
Free Cash Flow	-9.59M	-8.34M	-6.60M	-6.31M	-3.36M	-1.96M
Operating Cash Flow	-9.52M	-8.23M	-6.43M	-5.87M	-3.33M	-1.96M
Investing Cash Flow	6.97M	514.53K	3.25M	-13.48M	-30.66K	0.00
Financing Cash Flow	1.85M	7.38M	2.35M	0.00	21.32M	5.03M

BioRestorative Therapies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 1.62 is above the 20-day moving average (MA) of 1.52, above the 50-day MA of 1.52, and below the 200-day MA of 1.68, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 35.46 is Neutral, neither overbought nor oversold. The STOCH value of 26.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.

BioRestorative Therapies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRTX	48 Neutral	$11.95M	―	-137.09%	―	247.62%	-7.66%
MRKR	44 Neutral	$12.54M	―	-144.68%	―	44.55%	-17.92%
COCP	40 Underperform	$13.43M	-0.83	-110.56%	―	―	29.97%
SNSE	40 Underperform	$10.95M	-0.41	-67.47%	―	―	9.63%
CLRB	34 Underperform	$10.69M	-0.16	-273.88%	―	―	73.37%
AEON	24 Underperform	$11.05M	-0.16	―	―	―	-115.39%

BioRestorative Therapies Corporate Events

BioRestorative Clarifies Recent Press Release Details

BioRestorative Therapies has released a statement clarifying that the information in their recent press release is being furnished and not filed, and will not be incorporated into any registration statement unless specifically identified. The company emphasizes that this does not constitute a determination or admission that the information is material or complete, nor should it be considered by investors for making investment decisions.

BioRestorative Therapies Issues Regulation FD Disclosure

The news release does not contain specific information about BioRestorative Therapies’ industry, primary products or services, or market focus. The release appears to reference a Current Report on Form 8-K without providing substantial details about the company’s operations or implications for stakeholders.